Solid tumor malignancies

Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Done-hower RC, Carducci MA. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001 7 2292-2300. 

Elitek Rasburicase Sanofi-Synthelabo 7/2002 Management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies 5. cerevisiae... 

Aghajanian C, Soignet S, Dizon DS, Pez-zulli S,Daud A, etal. 2001. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. 

Allopurinol is used not only in treating the hyperuricemia associated with gout but also in the secondary hyperuricemia associated with the use of antineoplastic agents. Therefore, allopurinol may be used in the management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy that causes elevations of serum and urinary uric acid levels. Allopurinol may interfere with the metabolism of antineoplastic agents such as azathioprine and 6-mercaptopurine. 

Rasbnricase (Elitek) is a recombinant urate-oxidase that catalyzes the enzymatic oxidation of uric acid into the sol-nble and inactive metabolite allantoin. It has been shown to lower nrate levels more effectively than allopurinol. It is indicated in the initial management of elevated plasma nric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and significant hyperuricemia. 

CHAPTER 51 Antineoplastic Agents 901 solid tumor malignancies, including rituximab and alemtuzumab for lymphoid malignancies, and... 

Table 5 Selected clinical trials of monoclonal antibodies for the treatment of solid tumor malignancies... 

Thertulien R, Manikhas GM, Dirix LY et al (2012) Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 69 341-350 TrepakovaES, Koerner J, Pettit SD, Valentin JR HESl Pro-Arrhythmia Committee (2009) A HESI consortium approach to assess the human predictive value of non-chnical repolarization assays. J Pharmacol Toxicol Methods 60 45-50... 

Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, linette GP, Fu CJ, Pentikis HS, Zumbnm SC, Egorin MJ, Bellet RE. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 2009 63(3) 451-8. 

Collins C, Mortimer J, Livingston RB. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 1989 63 228-232. 

The chapters in Part VII and other parts clearly documented the potential value of NO donor molecules alone and in combination with chemo/radiotherapy in therapy of solid tumor malignancies. With all the supportive evidence generated to date. 

It has been demonstrated, mosdy in preclinical models, that NO donor molecules are selective and efficacious agents alone and in combination with cytotoxic therapy in a variety of solid tumor malignancies. Recent data (Lee et al. 2008) indicate that NO levels can be altered by activation of iNOS which in turn activate multiple targets such as EGFR, COX-2, HIF-la, and VEGF. These molecules that inhibit iNOS could have the potential for wide and selective alteration of multiple targets associated with tumor growth, metastasis, and resistance. Quintero and his... 

Despite the progress, the stark fact remains that the major solid tumors of people—lung, breast, colorectal, ovarian, and prostate—claim a great many lives and degrade the quality of life in the process. The drugs that we employ to battle these malignancies leave a lot to be desired. 

---